FuRui Medical Technology (01696.HK): Short-term performance disrupts during the transition period, concerns the injection sector is ready to go
FuRui Medical Technology (01696.HK): 2023 results are under pressure, and we expect China to strengthen the registration and filling business
FuRui Medical Technology (01696.HK): Short-term performance under multiple factors, pressure-pressurized injection lines are about to be approved domestically
Fu Rui Medical Technology (01696.HK): Leading medical and aesthetic energy source equipment to build a beautiful and healthy ecosystem
Fu Rui Medical Technology (1696.HK): The macro environment puts short-term pressure on mid-term results and the beauty ecosystem does not change its resilience
Fu Rui Medical Technology (01696.HK) 2023 Interim Report Review: Macro Environmental Factors and Channel Adjustments Drag Down Some Regional Majority Shareholders to Propose Repurchase, Showing Confidence
Fukui Medical Technology (1696.HK): Business transformation consolidation has led to slight adjustments in the short term and long-term development can still be expected
Fu Rui Medical Technology (1696.HK): 23H1 performance is temporarily under pressure and direct sales construction continues to strengthen
Fu Rui Medical Technology (01696.HK) Company Review: Mergers and Acquisitions Increase Direct Sales in China to Boost Gross Profit Growth
FuRui Medical Technology (01696.HK): Continued direct sales channel layout and strength of multiple business lines
Fu Rui Medical Technology (1696.HK): Medical, aesthetic and health platform with global channel layout and full business coverage
FuRui Medical Technology (1696.HK) In-depth Report: Leading Medical and Aesthetic Energy Source Products, Injection Products Ready to Go
Fu Rui Medical Technology (01696.HK): Another major drop in medical and aesthetic botulinum toxin listing application accepted
FuRui Medical Technology (01696.HK): China's direct sales layout made significant progress and acquired ALMALASERS distribution business
Furui Medical Technology (1696.HK): Direct sales continue to deepen in line with expectations
Furui Medical Technology (01696.HK): Profit growth rate of 20% + direct sales force, gross margin continues to increase
Furui Medical (1696.HK): Energy source equipment leader injectable products began to gain strength in '24
FuRui Medical Technology (01696.HK): The long-acting botulinum drug product DAXXIFY will be launched in the US and China will gain strength soon
Furui Medical Technology (01696.HK): Long-acting botulinum toxin FDA approval boosts confidence that Chinese clinical trials are progressing in an orderly manner
FuRui Medical Technology (01696.HK): Revenue increased 39%, diversified business development+channel integration ongoing
No Data